Daniel Wyzan, MD
Pulmonary Disease · Jacksonville, FLNPI 1598781643
Payments from drug & device makers
Across 240 payments — averaging $417.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$92K
- Pulmonx Corporation$2K
- AstraZeneca$2K
- Boehringer Ingelheim$1K
- Intuitive Surgical$813
- Actelion Pharmaceuticals US, Inc.$267
- plus $2K from 28 others
What the payments were for
- Speaking & faculty fees$87,72587%
- Travel & lodging$3,3223%
- Food & beverage$9,2039%
- Education$160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 81 | $91,583 |
| Pulmonx Corporation | 22 | $2,182 |
| AstraZeneca | 28 | $2,164 |
| Boehringer Ingelheim | 28 | $1,329 |
| Intuitive Surgical | 9 | $813 |
| Actelion Pharmaceuticals US, Inc. | 9 | $267 |
| Genentech USA, Inc. | 13 | $241 |
| Viiv Healthcare Company | 1 | $225 |
| Ambu Inc. | 3 | $133 |
| Inspire Medical Systems, Inc. | 1 | $128 |
| Vapotherm Inc | 1 | $123 |
| Merck | 1 | $122 |
| Edwards Lifesciences | 1 | $106 |
| United Therapeutics Corporation | 1 | $97 |
| Veran Medical Technologies, Inc. | 1 | $86 |
| Regeneron Healthcare Solutions, Inc. | 3 | $77 |
| Sanofi | 4 | $72 |
| Philips North America LLC | 4 | $69 |
| Insmed, Inc. | 4 | $64 |
| Gilead | 4 | $55 |
| Grifols USA, LLC | 3 | $51 |
| Pfizer | 3 | $42 |
| Mallinckrodt Enterprises LLC | 2 | $32 |
| Sunovion Pharmaceuticals Inc. | 2 | $30 |
| Mylan Specialty L.p. | 1 | $25 |
| Electromed, Inc. | 2 | $21 |
| Shire North American Group Inc | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Olympus America Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| AbbVie | 1 | $15 |
| Novartis | 1 | $15 |
| Bayer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$76,937
- Pulmonx Endobronchial Valve EBV$1,420
- FASENRA$1,280
- Da Vinci Surgical System$616
- OFEV$585
- NUCALA$240
- Inspire$128
- XOLAIR$125
- TAGRISSO$125
- BREZTRI$125
- Precision Flow$123
- AREXVY$122
- WINREVAIR$122
- AIRSUPRA$122
- HemoSphere$106
- CHARTIS CATHETER$102
- ZEPHYR DELIVERY CATHETER$102
- ZEPHYR ENDOBRONCHIAL VALVE$102
- PULMONX CHARTIS TABLET CONSOLE$102
How this compares
$100,266 in reported general payments places this provider in the 85th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 35 | $455,128 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 524 | $410,389 |
| OpsumitMacitentan | 12 | $151,412 |
| Dupixent PenDupilumab | 35 | $132,653 |
| Breo ElliptaFluticasone/Vilanterol | 191 | $86,093 |
| NucalaMepolizumab | 23 | $83,943 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 93 | $80,837 |
| Dupixent SyringeDupilumab | 19 | $72,141 |
| Spiriva RespimatTiotropium Bromide | 107 | $67,669 |
| TezspireTezepelumab-Ekko | 16 | $65,559 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 82 | $47,611 |
| SymbicortBudesonide/Formoterol Fumarate | 139 | $34,230 |
| Incruse ElliptaUmeclidinium Bromide | 35 | $13,347 |
| Arnuity ElliptaFluticasone Furoate | 48 | $13,341 |
| DuleraMometasone/Formoterol | 28 | $12,285 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Incruse Ellipta, Arnuity Ellipta | $91,583 | $616,847840 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $1,329 | $570,408224 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort | $2,164 | $180,627248 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $267 | $151,41212 claims |
| MerckDulera | $122 | $12,28528 claims |
| PfizerEliquis | $42 | $6,65912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Jacksonville
- Charles BurgerJacksonville$5.6M
- Abubakr BajwaJacksonville$1.4M
- Jennifer FultonJacksonville$791K
- Sebastian Fernandez-BussyJacksonville$559K
- Remzi BagJacksonville$556K
- Jose Soto SotoJacksonville$549K
- Augustine LeeJacksonville$533K
- Jorge MalleaJacksonville$478K
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.